Sangamo Therapeutics' ST-920 Gene Therapy Data and FDA Accelerated Approval Pathway: A Catalyst for Investors?

Sangamo Therapeutics has reported positive data from its Phase 1/2 STAAR study of ST-920 gene therapy for Fabry disease. The FDA has provided an Accelerated Approval pathway, and a rolling Biologics License Application submission has begun. The company's investment narrative is now centered on the BLA completion, review outcome, and funding. Investors should be aware of potential risks, including funding needs and dilution risk, and consider different fair value estimates from the Simply Wall St Community, which range from $1 to $26 per share.